A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems
Status:
Not yet recruiting
Trial end date:
2023-07-28
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to assess the effect of mild and moderate hepatic
impairment (Child-Pugh classification A and B) on the pharmacokinetics, safety, and
tolerability of BI 690517 in comparison with a control group with normal hepatic function.